KDx bladder cancer urine test gets breakthrough designation

By LabPulse.com staff writers

January 10, 2020 -- KDx Diagnostics said that its URO17 immunocytochemical biomarker test for detecting bladder cancer recurrence has received the breakthrough device designation from the U.S. Food and Drug Administration (FDA).

The test screens for keratin 17, a protein biomarker for urothelial cancer. It was invented by KDx co-founder Nam Kim, PhD, with research groundwork contributed by Dr. Kenneth Shroyer, PhD, chair of pathology at Stony Brook Medicine. KDx is positioning it as a noninvasive alternative to cystoscopy, which involves the insertion of a hollow tube with a lens through the urethra into the bladder.

In an initial study, the URO17 test in conjunction with urine cytology demonstrated sensitivity of 100% and specificity of 96% for detecting recurrent bladder cancer in urine samples.

LabCorp launches Qiagen's FGFR test for bladder cancer
LabCorp announced on May 10 that it has begun offering Qiagen's therascreen companion diagnostic for detecting fibroblast growth factor receptor (FGFR)...
Natera touts liquid biopsy in bladder cancer
Results from Natera's prospective study validating its Signatera circulating tumor DNA (ctDNA) test in urothelial bladder cancer were published online...

Copyright © 2020 LabPulse.com

Last Updated np 1/9/2020 3:48:43 PM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email